98%
921
2 minutes
20
Leiomyosarcoma is a rare malignant mesenchymal tumor characterized by smooth muscle differentiation. It typically arises in both visceral and somatic soft tissues, while involvement of bone being exceptionally uncommon. Although primary leiomyosarcoma of bone has been a subject of ongoing debate, the advent of immunohistochemistry has reduced the misclassification of other sarcomas, such as fibrosarcoma and undifferentiated pleomorphic sarcoma, facilitating the accurate identification of true primary LMSB cases. To date, just over 200 well-documented LMSB cases have been published in English-language literature. Despite this, understanding of its clinical behaviour and factors influencing patient outcomes remains limited. In this study, we present the clinical, pathological, and immunohistochemical findings from 142 cases of primary bone leiomyosarcoma including extended follow-up data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236143 | PMC |
http://dx.doi.org/10.32074/1591-951X-N1251 | DOI Listing |
Purpose: PTEN loss contributes to aberrant signaling of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B/mammalian target of rapamycin pathway and may confer sensitivity to therapies targeting the PI3K pathway. The PIK3CB inhibitor GSK2636771 demonstrated efficacy in tumors with mutations and may similarly show efficacy in patients with PTEN loss.
Methods: Two nonrandomized, open-label phase II subprotocols within the context of the NCI-MATCH trial targeted PTEN tumor alterations in patients with advanced relapsed/refractory solid tumors, lymphoma, or myeloma: mutation/deletion (arm N) or loss of PTEN protein expression (arm P).
Mol Imaging Biol
August 2025
Harvard Medical School, Boston, MA, USA.
Purpose: Sarcomas, malignancies of mesenchymal origin, present significant diagnostic and therapeutic challenges due to their heterogeneity and low incidence. This review aims to examine the evolving role of fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the management of soft tissue and musculoskeletal sarcomas. Specifically, it seeks to evaluate 18F-FDG PET/CT's utility in detecting metastatic lesions, differentiating benign from malignant tumors, and assessing treatment responses.
View Article and Find Full Text PDFAnn Surg Oncol
August 2025
Biomedical Imaging Group Rotterdam, Department of Radiology & Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
Background: Obtaining an accurate preoperative diagnosis in retroperitoneal sarcoma (RPS) is challenging, and radiomics-based models may offer a valid option to achieve this outcome. This study evaluated the accuracy of radiomics-based preoperative CT models at predicting tumour histology and grade in patients with primary RPS.
Methods: Data on consecutive patients who underwent surgery for primary retroperitoneal liposarcoma (RLPS) and leiomyosarcoma (RLMS) were analysed.
J Clin Ultrasound
August 2025
Department of Ultrasound Medicine, Jining NO. 1 People's Hospital, Jining, China.
Primary hepatic leiomyosarcoma (PHLS) is a rare malignant tumor of mesenchymal origin in the liver, with nonspecific clinical manifestations. High fever as the initial symptom is uncommon, making it easily misdiagnosed as a liver abscess. In this case, the tumor was initially mistaken for a liver abscess.
View Article and Find Full Text PDFJ Surg Case Rep
August 2025
Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Boulevard Goce Delchev 9, Skopje 1000, North Macedonia.
Rectal leiomyosarcoma (LMS) is an exceptionally rare malignancy, representing ˂0.5% of all rectal cancers. Even more uncommon are the cases of radiation-induced LMS arising as an independent malignancy following pelvic radiotherapy.
View Article and Find Full Text PDF